Navigation Links
Meditor Pharmaceuticals (North American) Ltd. announces the closing of a merger agreement with American Medical Technologies, Inc.
Date:3/12/2009

TORONTO, March 12 /PRNewswire/ - Meditor Pharmaceuticals Ltd (Trading as M20.F) is pleased to announce it has concluded a merger agreement with AMERICAN MEDICAL TECHNOLOGIES, INC. (AMT).

AMERICAN MEDICAL TECHNOLOGIES, INC. is a U.S. based company which performs biomedical research dedicated to the development and commercialization of proprietary Blood Cell Morphometric Method (BCMM) technology. Its purpose is to detect early cancer in patients where traditional methods do not work.

As a result of the continuous scientific research activity since 1985 a comprehensive Patent was filed in Russia for a "Method for diagnosing human tumor disorders".

Our method, which has already proved to be beneficial to hundreds of patients, reduces the risk for the planned clinical trials and shortens the time to the market. Upon the completion of the automatic analysis and before all the clinical trials are completed, our technology can be applied to many countries and has unlimited use in the alternative medicine market today.

AMT's Research and Development operations are based in USA, Germany and Ukraine, and conducted through the lab in New York and clinical applications in Ukraine. AMT's management team consists of Dr. Boris Farber (CEO and Chairman of the Board), Dr. Evgenia Skobeltzin (Leading Scientist R&D), and Tatiana Skobeltzin (Administration Manager, Germany).

According to Dr. Farber, with our unique Blood Cell Morphometric Method, we will be able to provide new and effective technology to deal with early cancer detection in healthy individuals and monitor the treatment efficiency in patients diagnosed with cancer. This will revolutionize the field of oncology and may become a new standard of care in this $219.2 billion market.

In additional news, Mr. Larry Skolnik, President of MEDITOR and Dr. Boris Farber, CEO and Chairman of AMT are continuing to develop relationships with market makers in Europe to help create additional investor awareness of Meditor and AMT on the Frankfurt and Berlin Exchanges.

The company's first stop on its investor relations tour will be in Munich this Monday 16 March 2009 at Hotel Le Meridien in the Elysee II Suite.

Disclaimer

This release may contain certain "forward-looking statements" with respect to certain of Indenture Investments Ltd's plans and its current goals and expectations relating to its future financial condition, performance, results, strategy and objectives. Statements containing the words "believes", "intends", "expects", "plans", "seeks" and "anticipates", and words of similar meaning, are forward-looking. By their nature, all forward-looking statements involve risk and uncertainty because they relate to future events and circumstances which are beyond Indenture Investments Ltd's control including among other things, Canadian domestic and global economic and business conditions, market related risks, and the performance of financial markets generally; the policies and actions of regulatory authorities, the impact of competition, inflation, and deflation; the timing, impact and other uncertainties of future acquisitions or combinations within relevant industries; and the impact of changes in capital, solvency or accounting standards, and tax and other legislation and regulations in the jurisdictions in which Indenture Investments Ltd. operates. As a result, Indenture Investments Ltd's actual future financial condition, performance and results may differ materially from the plans, goals, and expectations set forth in Indenture Investments Ltd's forward-looking statements. Indenture Investments Ltd. undertakes no obligation to update the forward-looking statements contained in this section or any other forward-looking statements it may make.


'/>"/>
SOURCE Meditor Pharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Gamma Pharmaceuticals Accepts PO From Leading St. Louis Missouri Distributor. Order Valued up to $850,000 Retail Market Value
2. MAP Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
3. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
4. ISTA Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
5. Biostar Pharmaceuticals, Inc. Completes 8.6-Acre Land Purchase to House New Raw Materials Processing Plant
6. Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Cowen & Companys 29th Annual Health Care Conference in Boston on March 16, 2009
8. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
9. Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
10. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
11. Merz Aesthetics, a Division of Merz Pharmaceuticals USA, Introduces a Universal Language of Aging for Use in Education, Research and Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... July 27, 2017 , ... ... 2012-2016, will keynote Day 2 of the HIMSS Healthcare Security Forum, the nation’s ... the Sheraton Boston Hotel, Sept. 11-13, 2017. , Daniel will deliver his keynote, ...
(Date:7/26/2017)... ... July 26, 2017 , ... Evergreen Healthcare Partners ... their continued efforts to provide innovative offerings to their healthcare partners. These solutions ... build dynamic, high-performing teams to address healthcare IT’s biggest challenges. , “Adding Talent ...
(Date:7/26/2017)... ... ... time to sign up for the new One-A-Month Essential Oil Club for fun and ... Naturals and author of numerous books on essential oils. , , ... , Two items are included in the December mailing. , A ...
(Date:7/26/2017)... Michigan (PRWEB) , ... July 26, 2017 , ... ... appointed Medical Director for the treatment program located in Royal Oak, Michigan. ... of investors who are focused on providing the highest standards in the field of ...
(Date:7/26/2017)... ... 2017 , ... The number of adults 65 years or older is expected ... asthma control in the population are not well described. In a study published in ... journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), researchers identified factors ...
Breaking Medicine News(10 mins):
(Date:7/24/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... 2017 operating results on Monday, August 7, 2017 after ... 5:00 p.m. ET. ... broadcast of the conference call by dialing 877-201-0168 or ... approximately 15 minutes prior to the call. A live ...
(Date:7/21/2017)... and RESEARCH TRIANGLE PARK, N.C. ... Corporation (NASDAQ: UTHR ) announced today that ... before the market opens on Thursday, July 27, 2017. ... host a teleconference on Thursday, July 27, 2017, at ... dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast ...
(Date:7/21/2017)... , July 21, 2017 Did you know that ... in 2016? Or that combined spending on brand medicines, generics and ... spending, with brands accounting for just half of this (7 percent)? ... two thirds of the world,s venture capital investments in high-growth biopharmaceutical ... ...
Breaking Medicine Technology: